We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience, read our Cookie Policy

Oncolytics Meets Primary Endpoint for First Stage of U.S. Phase 2 SCLC Clinical Trial

News   Feb 01, 2013

 
Oncolytics Meets Primary Endpoint for First Stage of U.S. Phase 2 SCLC Clinical Trial
 
 
 

RELATED ARTICLES

New Hope for Aggressive Breast Cancer: Diabetes Drug Creates Treatment “Sweet Spot”

News

New research funded by Breast Cancer Now has shown that a drug commonly used to treat Type 2 diabetes could make breast cancer cells susceptible to new treatments.

READ MORE

Injecting Dying Cells to Trigger Tumor Destruction

News

By directly injecting engineered dying cells into tumors, researchers have successfully triggered the immune system to attack the cancerous cells at multiple sites within the body and reduce tumor growth, in mice.

READ MORE

Cancer Control: Researchers Solve the Structure of Important Transport Protein

News

Scientists have published the first structure of a lactate-transporter of the SLC16-family (SfMCT) that may have therapeutic benefit in cancer.

READ MORE

 

Like what you just read? You can find similar content on the communities below.

Drug Discovery

To personalize the content you see on Technology Networks homepage, Log In or Subscribe for Free

LOGIN SUBSCRIBE FOR FREE